{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:21:24Z","timestamp":1794565284911,"version":"4.9.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment of mantle cell lymphoma (MCL) in younger patients remains a challenge. We report results of a phase 2 trial using cytarabine and rituximab as induction regimen before autologous stem cell transplantation. Patients younger than 66 years with stage 3 or 4 MCL were included. Treatment consisted of 3 courses of CHOP21 with rituximab at the third one and 3 of R-DHAP. Responding patients were eligible for autologous stem cell transplantation with TAM6 or BEAM. Sixty patients were included. Median age was 57 years. Characteristics of patients were: BM involvement 85%, leukemic disease 48%, gastrointestinal involvement 52%, Performance Status &gt; 16%, lactate dehydrogenase &gt; 1N 38%, Mantle Cell Lymphoma International Prognostic Index (low 55%, intermediate 38%, high 13%). The overall response rate was 93% after (R)-CHOP and 95% after R-DHAP. Although uncommon after (R)-CHOP (12%), 57% of patients were in complete response after R-DHAP. With median follow-up of 67 months, median event-free survival is 83 months, and median overall survival is not reached. Five-year overall survival is 75%. Comparison with a previous study without rituximab shows improvement of outcome (median event-free survival, 51 vs 83 months). No toxic death or unexpected toxicities were observed. This study confirms that induction with rituximab and cytarabine-based regimens is safe and effective in MCL patients. This regimen is currently compared with R-CHOP21 induction in a multicentric European protocol.<\/jats:p>","DOI":"10.1182\/blood-2011-09-370320","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T09:07:31Z","timestamp":1340269651000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":231,"title":["CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte"],"prefix":"10.1182","volume":"121","author":[{"given":"Richard","family":"Delarue","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie, Hopital Necker, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Hopital Henri Mondor, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Institut Gustave Roussy, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Hopital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Hopital Robert Debre, Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Tilly","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Centre Henri Becquerel, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Centre Hospitalier Lyon Sud, Pierre-Benite, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, AZ St Jan, Brugge, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Service d'Hematologie, Hopital du Bocage, Dijon, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brousse","sequence":"additional","affiliation":[{"name":"Service d'Anatomie Pathologique, Hopital Necker, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Lefrere","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Hopital Necker, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Hopital Necker, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111808590374600_B1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.","volume":"2009","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2019111808590374600_B2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/10428190903503453","article-title":"Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop.","volume":"51","author":"Williams","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111808590374600_B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"issue":"26","key":"2019111808590374600_B4","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808590374600_B5","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111808590374600_B6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111808590374600_B7","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111808590374600_B8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019111808590374600_B9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.","volume":"16","author":"Lefr\u00e8re","year":"2002","journal-title":"Leukemia"},{"issue":"4","key":"2019111808590374600_B10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111808590374600_B11","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808590374600_B12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111808590374600_B13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.","volume":"144","author":"van 't Veer","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808590374600_B14","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"2019111808590374600_B15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111808590374600_B16","first-page":"688","article-title":"Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the Lymphoma Working Party of the EBMT [abstract].","volume":"116","author":"Rubio","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"39","key":"2019111808590374600_B17","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1038\/sj.onc.1206826","article-title":"Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma.","volume":"22","author":"M'kacher","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"2019111808590374600_B18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdf042","article-title":"Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?","volume":"13","author":"Barista","year":"2002","journal-title":"Ann Oncol"},{"issue":"13","key":"2019111808590374600_B19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.","volume":"113","author":"Be\u00e0","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111808590374600_B20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1399-0004.2008.00987.x","article-title":"ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1\/BRCA2 mutations.","volume":"73","author":"Brunet","year":"2008","journal-title":"Clin Genet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/1\/48\/1363075\/zh800113000048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/1\/48\/1363075\/zh800113000048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:03:31Z","timestamp":1574071411000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/1\/48\/31039\/CHOP-and-DHAP-plus-rituximab-followed-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-370320","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948630.793453739","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717948630.793455900","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}